nafamostat has been researched along with Lung Diseases in 1 studies
nafamostat: inhibitor of trypsin, plasmin, pancreatic kallikrein, plasma kallikrein & thrombin; strongly inhibits esterolytic activities of C1r & C1 esterase complement-mediated hemolysis; antineoplastic
Lung Diseases: Pathological processes involving any part of the LUNG.
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 0 (0.00) | 18.2507 |
| 2000's | 1 (100.00) | 29.6817 |
| 2010's | 0 (0.00) | 24.3611 |
| 2020's | 0 (0.00) | 2.80 |
| Authors | Studies |
|---|---|
| Kotani, K | 1 |
| Ichiba, S | 1 |
| Andou, M | 1 |
| Sano, Y | 1 |
| Date, H | 1 |
| Tedoriya, T | 1 |
| Goto, K | 1 |
| Shimizu, N | 1 |
1 other study available for nafamostat and Lung Diseases
| Article | Year |
|---|---|
Extracorporeal membrane oxygenation with nafamostat mesilate as an anticoagulant for massive pulmonary hemorrhage after living-donor lobar lung transplantation.
Topics: Acute Disease; Adult; Anticoagulants; Benzamidines; Combined Modality Therapy; Extracorporeal Membra | 2002 |